Multiple PANC-1-derived tumor-associated antigens and neoantigens (PANC-1 TAAs/Neoantigens)

Multiple PANC-1-derived tumor-associated antigens and neoantigens represent a broad spectrum of immunogenic targets sourced from the PANC-1 human pancreatic ductal adenocarcinoma cell line (ATCC CRL-1469). This cell line is frequently utilized in oncology research and clinical trials to develop whole-cell vaccines, such as GVAX Pancreas, or to pulse dendritic cells for personalized immunotherapy (PubMed: 25852126). The antigenic profile includes overexpressed tumor-associated antigens (TAAs) like mesothelin (MSLN), mucin 1 (MUC1), and carcinoembryonic antigen (CEA), as well as neoantigens arising from specific mutations, most notably the KRAS G12D mutation (PubMed: 25135396, UniProt: P01116). By targeting multiple antigens simultaneously, these therapeutic approaches aim to mitigate the risk of immune escape caused by the high heterogeneity of pancreatic tumors (PubMed: 30643214). Drugs interacting with these targets work by enhancing the presentation of these antigens to the immune system, thereby priming CD8+ cytotoxic T-cells and CD4+ helper T-cells to recognize and destroy malignant cells (PubMed: 21444874). This multi-target strategy is particularly relevant in pancreatic cancer, where the dense stroma and immunosuppressive microenvironment pose significant challenges to single-antigen therapies. Clinical monitoring often involves assessing the expression of specific TAAs like mesothelin or the presence of mutation-specific T-cell responses (PubMed: 11506501).

Other names

PANC-1 cell lysate antigensPANC-1 tumor antigensPancreatic cancer cell line-derived antigensPANC-1 whole-cell antigens

Induction of a multi-antigenic T-cell mediated immune response against pancreatic cancer cells through the presentation of tumor-associated antigens and neoantigens by professional antigen-presenting cells (PubMed: 21444874).